SHENGDA BIO-PHARM(SH:603079)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥181,078,069.43, a decrease of 2.37% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥2,645,195.73, down 56.36% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥678,266.79, a decline of 80.55% compared to the previous year[5]. - The basic earnings per share for Q3 2023 was ¥0.02, down 50.00% from the same period last year[6]. - The diluted earnings per share for Q3 2023 was also ¥0.02, reflecting a 50.00% decrease year-on-year[6]. - The weighted average return on equity for Q3 2023 was 0.20%, a decrease of 0.25 percentage points compared to the previous year[6]. - Total revenue for the first three quarters of 2023 reached ¥544,108,238.57, a slight increase from ¥535,910,347.16 in the same period of 2022, representing a growth of approximately 0.37%[23]. - The net profit for the third quarter of 2023 was a loss of ¥2,626,697.31, compared to a profit of ¥44,947,249.32 in the same quarter of 2022, reflecting a significant decline[24]. - Total comprehensive income for Q3 2023 was -2,626,697.31 CNY, compared to 44,947,249.32 CNY in Q3 2022[25]. - Basic and diluted earnings per share for Q3 2023 were both -0.02 CNY, down from 0.27 CNY in Q3 2022[25]. Cash Flow and Liquidity - The cash flow generated from operating activities for the year-to-date period was ¥15,363,815.47, a decrease of 61.97% year-on-year[5]. - Cash inflow from operating activities for the first three quarters of 2023 was 591,147,959.53 CNY, a decrease of 6.2% from 630,334,909.14 CNY in the same period of 2022[28]. - Net cash flow from operating activities for the first three quarters of 2023 was 15,363,815.47 CNY, down 62.0% from 40,397,337.23 CNY in the first three quarters of 2022[28]. - Cash flow from investing activities for the first three quarters of 2023 was -149,919,673.60 CNY, compared to -109,837,241.90 CNY in the same period of 2022[28]. - Cash flow from financing activities for Q3 2023 was 129,183,362.70 CNY, a significant improvement from -143,534,590.54 CNY in Q3 2022[29]. - The cash and cash equivalents at the end of Q3 2023 were 300,424,462.60 CNY, slightly down from 295,505,721.53 CNY at the end of Q3 2022[29]. - The company received 22,160,453.32 CNY in tax refunds during Q3 2023, down from 38,209,932.82 CNY in Q3 2022[28]. - The company's cash and cash equivalents amounted to RMB 326,016,344.18, an increase from RMB 320,717,851.36 at the end of 2022[17]. - The company's cash and cash equivalents decreased from ¥780,363,496.40 in the previous quarter to ¥745,109,973.56 in the current quarter, a decline of about 4.5%[20]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥1,700,300,360.14, an increase of 2.72% from the end of the previous year[6]. - The company's total assets as of the end of the third quarter of 2023 amounted to ¥1,700,300,360.14, an increase from ¥1,655,207,544.77 at the end of the previous year[22]. - Total liabilities increased to ¥376,170,608.80 in the third quarter of 2023, compared to ¥311,761,934.11 in the same quarter of 2022, marking an increase of approximately 20.61%[20]. - The total equity attributable to shareholders decreased from ¥1,327,997,339.73 in the previous year to ¥1,307,620,381.15 in the current year, a decline of about 1.3%[20]. - The equity attributable to shareholders at the end of Q3 2023 was ¥1,307,620,381.15, a decrease of 1.53% compared to the previous year[6]. Shareholder Information - The total number of shares held by the top 10 shareholders includes Zhejiang Shengda Group Co., Ltd. with 45,375,792 shares, accounting for 26.51% of total shares[12]. - The company has not disclosed any other significant relationships among shareholders beyond those already mentioned[13]. - The company has repurchased a total of 531,800 shares, representing 0.31% of the total share capital, with a total expenditure of RMB 6,417,107.00[16]. - The highest repurchase price of shares was RMB 12.21 per share, while the lowest was RMB 11.90 per share[16]. Future Plans and Investments - The company plans to issue up to 51,356,687 A-shares, raising a total of no more than RMB 500 million for production projects[14]. - The company has a plan to invest in the production of 3 billion soft capsules and 3 billion solid preparations, along with a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[14]. Operational Performance - The significant decline in net profit is attributed to weakened downstream demand for vitamin products, leading to a market imbalance and reduced profit margins[10]. - The company reported a decrease in cash received from sales of goods and services, totaling 550,016,397.31 CNY in the first three quarters of 2023, compared to 565,252,581.30 CNY in the same period of 2022[27]. - The company incurred 406,731,984.21 CNY in cash payments for goods and services in the first three quarters of 2023, down from 441,698,753.65 CNY in the same period of 2022[28]. - Research and development expenses for the first three quarters of 2023 were ¥30,185,572.78, compared to ¥28,221,474.03 in the same period of 2022, showing an increase of approximately 6.96%[23]. - The company has reported a financial expense of -¥8,496,473.01 for the first three quarters of 2023, a significant improvement compared to -¥23,186,210.60 in the same period of 2022[23].